Navigation Links
Colorectal Cancer (CRC) Screening Market for Diagnosis & Treatment 2018 Forecasts in New Research Report at RnRMarketResearch.com
Date:8/12/2013

Dallas, Texas (PRWEB) August 12, 2013

Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. The prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC screening programs, mortality in the developed countries is falling; however incidence continues to rise as a result of diet and increasingly sedentary lifestyles. While historically, colorectal cancer incidence in the developing world is low, in recent years, disease diagnosis rates have dramatically increased, as a result of changing lifestyles, awareness and improved access to medical services. CRC screening can improve survival rates, and reduce the overall cost of patient treatment.

Get a copy of this report @ http://www.rnrmarketresearch.com/medipoint-in-vitro-colorectal-cancer-screening-tests-global-analysis-and-market-forecasts-market-report.html.

Questions Answered in this Report:
Colorectal cancer can be caused by somatic mutations as well as inherited mutations. These mutations lead to changes in the colon that can be detected by detection of bleeding. But many of these mutations can also be detected by genetic and other tests. How quickly will new gene tests be adopted by the CRC screening market?

What are the key differences in CRC screening carried out in different countries, and how will these differences affect adoption of new screening tests?

Existing CRC screening is based on inexpensive, but inaccurate stool analysis tests, or expensive but accurate endoscopies. The first DNA screening tests are expected to come to market in 2014, from Exact Sciences and EpiGenomics. Which new DNA-based screening test will win out?

In-vitro CRC screening is a fast evolving technological area. How will changes in technology affect sales of existing CRC screening tests? Who are the new players in CRC screening? How will patient attitudes affect the In-vitro CRC screening test market?

Major Company Profiles:
1 Abbott Molecular
2 Alere
3 Beckman Coulter
4 Biomarcare Technologies
5 Companion Dx
6 Eiken Chemical
7 Epigenomics
8 Exact Sciences
9 ExiQon
10 Fujirebio (Miraca Holdings)
11 GeneNews
12 GenomicTree
13 Immunostics
14 Kyowa Medex
15 MDx Health (was OncoMethylome)
16 Merck Millipore
17 Metabiomics
18 Mode Diagnostics
19 Oncocyte (Bio Time)
20 Quest Diagnostics
21 R-Biopharm
22 Randox Laboratories
23 Schebo Biotech
24 SciMarket Technologies
25 Siemens Healthcare
26 Signature Diagnostics
27 Sysmex
28 Veda Lab

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=110513.

Browse more reports on Cancer Diagnostics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/diagnostics/in-vitro-diagnostics-ivd/cancer-diagnostics.

About Us:
RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/invitro-colorectal-cancer/screening-market-analysis/prweb11017353.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
2. Study says screening accounts for much of black/white disparity in colorectal cancer
3. Blacks and Hispanics at higher risk for precancerous colorectal polyps
4. Geisel researchers sift through junk to find colorectal cancer clues
5. Blood pressure drugs dont protect against colorectal cancer
6. NIH study finds sigmoidoscopy reduces colorectal cancer rates
7. Colonoscopy screening markedly reduces colorectal cancer incidence and death
8. Surgical patient safety program lowers SSIs by one-third following colorectal operations
9. A recipe for increased colorectal cancer screening rates
10. Gene mutation identifies colorectal cancer patients who live longer with aspirin therapy
11. New electrically-conductive polymer nanoparticles can generate heat to kill colorectal cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
Breaking Medicine Technology: